APA (7th ed.) Citation

Amat‐Santos, I. J., Sánchez‐Luna, J. P., Abu‐Assi, E., Melendo‐Viu, M., Cruz‐Gonzalez, I., Nombela‐Franco, L., . . . Pereiro‐Montes, D. (2022). Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial. European Journal of Heart Failure, 24(3), 581. https://doi.org/10.1002/ejhf.2370

Chicago Style (17th ed.) Citation

Amat‐Santos, Ignacio J., et al. "Rationale and Design of the Dapagliflozin After Transcatheter Aortic Valve Implantation (DapaTAVI) Randomized Trial." European Journal of Heart Failure 24, no. 3 (2022): 581. https://doi.org/10.1002/ejhf.2370.

MLA (9th ed.) Citation

Amat‐Santos, Ignacio J., et al. "Rationale and Design of the Dapagliflozin After Transcatheter Aortic Valve Implantation (DapaTAVI) Randomized Trial." European Journal of Heart Failure, vol. 24, no. 3, 2022, p. 581, https://doi.org/10.1002/ejhf.2370.